Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gabapentin + methylcobalamin is a fixed-dose combination prescription medication primarily indicated for the management of neuropathic pain associated with conditions such as diabetic neuropathy, post-herpetic neuralgia, and peripheral neuropathy. The combination leverages two distinct mechanisms: **gabapentin**, an anticonvulsant, acts as an alpha-2-delta ligand that binds to the α2δ-1 subunit of voltage-gated calcium channels in the central nervous system, thereby reducing the release of excitatory neurotransmitters and modulating abnormal pain signals. **Methylcobalamin**, a neurologically active form of vitamin B12, serves as a cofactor for the enzyme methionine synthase, which is essential for the synthesis of myelin. By promoting myelin sheath regeneration and protecting nerve fibers from further damage, methylcobalamin supports nerve repair and improves nerve conduction velocity. This synergistic approach addresses both the symptomatic transmission of pain and the underlying nerve damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gabapentin + methylcobalamin.